Fig. 6: MARQO identifies CD8 T cell enrichment in responders to anti-PD1 treatment.
a, After classification and review, we identified Treg cells (CD3+FOXP3+CD8−), macrophages (CD68+), B cells (CD20+) and CD8 T cells (CD3+CD8+) and evaluated their densities across whole-slide tissues for responders and non-responders (NRs) to cemiplimab treatment at baseline and post-treatment. b, Representative image showing the overlay of the tissue with the annotation made by the pathologist using QuPath to demarcate tissue region boundaries, including tumour, adjacent, fibrosis and necrosis, for all tissues used. Scale bar, 500 µm. c, Pie charts depicting the tissue compartments annotated by a pathologist for all samples at baseline and post-treatment for responders (n = 4 and 6, respectively) and non-responders (n = 12 for both). d, CD8 T cell densities plotted at baseline and post-treatment for NR and responder groups within tumour (n = 27), fibrosis (n = 18) and necrosis (n = 15) compartments. Data are presented as mean ± s.e.m. Multigroup analyses of variance were performed using one-way analysis of variance followed by Å Ãdák one-way comparison tests. e, Bar plots depicting the means of the shortest distances from CD8 T cells to themselves (left), to B cells (middle) and to Treg cells (right) at baseline and post-treatment for non-responders and responders within tumour (n = 27), fibrosis (n = 18) and necrosis (n = 15) compartments. Data are presented as mean ± s.e.m. Multigroup analyses of variance were performed using one-way analysis of variance followed by Å Ãdák one-way comparison tests.
